JP4666652B2 - Oral skin improver containing cranberry extract as an active ingredient - Google Patents
Oral skin improver containing cranberry extract as an active ingredient Download PDFInfo
- Publication number
- JP4666652B2 JP4666652B2 JP2006510238A JP2006510238A JP4666652B2 JP 4666652 B2 JP4666652 B2 JP 4666652B2 JP 2006510238 A JP2006510238 A JP 2006510238A JP 2006510238 A JP2006510238 A JP 2006510238A JP 4666652 B2 JP4666652 B2 JP 4666652B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- oral
- oral skin
- cranberry extract
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は、クランベリー抽出物を有効成分とする経口用皮膚改善剤に関する。 The present invention relates to an oral skin improver comprising a cranberry extract as an active ingredient.
クランベリー(Vaccinium macrocarpon Ait.)は、北アメリカなどの寒冷地に生育するツツジ科スノキ属ツルコケモモ節の植物であり、小果実を実らせる。アメリカでは品種改良が行われて大規模に栽培されている。クランベリー果実はそのままでも食せるが、これまでドライフルーツとして、またジュースなどの飲料用、料理用ソース、ジャム、ゼリー菓子などの原料として広く利用されている。またクランベリージュースの摂取が、尿路感染症に有効であることが知られている(非特許文献1参照。)。 Cranberry (Vaccinium macrocarpon Ait.) Is a plant of the Azalea family Vulgaris genus Cloverberry that grows in cold regions such as North America and grows small fruits. In the United States, varieties have been improved and cultivated on a large scale. Although cranberry fruits can be eaten as they are, they have been widely used as dried fruits and as raw materials for beverages such as juice, cooking sauces, jams, and jelly sweets. In addition, it is known that ingestion of cranberry juice is effective for urinary tract infections (see Non-Patent Document 1).
従来、クランベリーを用いた化粧品の例として、主としてアントシアニン重合体からなるクランベリーの実の圧搾濾過物及び/又は抽出物からなる皮膚ひきしめ剤および化粧料(特許文献1参照。)、クランベリー果実搾汁液及び/又はクランベリー果実抽出物と、美白剤、抗酸化剤、抗炎症剤、細胞賦活剤、紫外線防止剤などの薬効剤を含有する皮膚外用剤(特許文献2参照。)などが知られている。しかしながら、これらはいずれも皮膚外用剤であり、経口用途については知られていなかった。
本発明の目的は、クランベリー抽出物を有効成分とする経口用皮膚改善剤を提供することである。 An object of the present invention is to provide an oral skin improver comprising a cranberry extract as an active ingredient.
本発明者らは、上記課題を解決するために鋭意研究した結果、クランベリー抽出物が、経口用皮膚改善剤として有用であることを見出し、本発明を完成した。すなわち本発明は、以下に記載する経口用皮膚改善剤である。 As a result of intensive studies to solve the above-mentioned problems, the present inventors have found that the cranberry extract is useful as an oral skin improvement agent and completed the present invention. That is, this invention is an oral skin improvement agent described below.
(1)クランベリー抽出物を有効成分とすることを特徴とする経口用皮膚改善剤。(1) An oral skin improvement agent comprising a cranberry extract as an active ingredient.
(2)経口用皮膚改善剤が、皮膚の保湿、皮脂量調節、皮膚の弾力性保持または抹消血液循環保持のいずれか1つ以上の機能を有することを特徴とする、上記(1)記載の経口用皮膚改善剤。(2) The oral skin improver has one or more of the functions of moisturizing the skin, adjusting the amount of sebum, maintaining the elasticity of the skin, or maintaining the peripheral blood circulation, (1) Oral skin improver.
(3)上記(1)または(2)に記載の経口用皮膚改善剤を含有することを特徴とする、飲食品または医薬品。(3) A food or drink or a pharmaceutical comprising the oral skin improver according to (1) or (2).
本発明は、クランベリー抽出物を有効成分とする経口用皮膚改善剤である。 The present invention is an oral skin improver comprising a cranberry extract as an active ingredient.
有効成分であるクランベリー抽出物とは、例えば、常法によりクランベリー果実から搾汁して得られた果汁もしくはその果汁を濃縮したもの、前記果汁もしくは濃縮果汁にデキストリンなどの賦形剤を添加混合し噴霧乾燥あるいは凍結乾燥するなどの手段で得られたクランベリー果汁中の固形分を含有するもの、またはクランベリーの果実や果皮・種子より適当な溶剤を用いて抽出された抽出物などをいう。これらのクランベリー抽出物は経口摂取により、皮膚改善作用を発揮する。 The cranberry extract as an active ingredient is, for example, a fruit juice obtained by squeezing cranberry fruit by a conventional method or a concentrate thereof, and an excipient such as dextrin is added to and mixed with the fruit juice or the concentrated fruit juice. This refers to those containing solid content in cranberry juice obtained by means such as spray drying or freeze drying, or extracts extracted from cranberry fruits, pericarps and seeds using a suitable solvent. These cranberry extracts exhibit an effect of improving the skin when taken orally.
本発明において得られるクランベリー抽出物中の有効成分としては、例えば、プロアントシアニジン、アントシアニン、フラボノール配糖体等のポリフェノール、キナ酸、クエン酸等の有機酸、無機物及びビタミン等が挙げられる。これらの中でも、プロアントシアニジン、アントシアニン等のポリフェノール、キナ酸等の有機酸を多く含有するものが好ましい。 Examples of the active ingredient in the cranberry extract obtained in the present invention include polyphenols such as proanthocyanidins, anthocyanins and flavonol glycosides, organic acids such as quinic acid and citric acid, inorganic substances and vitamins. Among these, those containing a large amount of polyphenols such as proanthocyanidins and anthocyanins and organic acids such as quinic acid are preferable.
抽出処理に用いる溶剤は特に限定されず、通常の極性溶媒、両極性溶媒等が使用できる。溶剤としては、例えば、水、有機溶媒またはそれを含む溶剤、水と有機溶媒との混合液等が使用できる。有機溶媒としては例えば、低級アルコール(具体的にはエタノール、メタノール、プロパノール、ブタノール)、エーテル類(具体的にはジエチルエーテル)、ハロゲン化炭化水素(具体的にはクロロホルム)、ニトリル類(具体的にはアセトニトリル)、エステル類(具体的には酢酸エチル)、ケトン類(具体的にはアセトン)などの他に、ヘキサン、ジメチルスルホキシド、ジメチルホルムアミド等であるが、作業性の面から、エタノール、メタノール、または、酢酸エチルが好ましい。有機溶媒は2種以上を混合して使用しても良い。 The solvent used for the extraction treatment is not particularly limited, and a normal polar solvent, a bipolar solvent, or the like can be used. As the solvent, for example, water, an organic solvent or a solvent containing the same, a mixed solution of water and an organic solvent, or the like can be used. Examples of the organic solvent include lower alcohols (specifically ethanol, methanol, propanol, butanol), ethers (specifically diethyl ether), halogenated hydrocarbons (specifically chloroform), nitriles (specifically In addition to acetonitrile), esters (specifically ethyl acetate), ketones (specifically acetone), etc., there are hexane, dimethyl sulfoxide, dimethylformamide, etc., but from the viewpoint of workability, ethanol, Methanol or ethyl acetate is preferred. Two or more organic solvents may be mixed and used.
なお、クランベリー抽出物中の有効成分を濃縮・精製するために更なる溶媒抽出、合成吸着剤やイオン交換樹脂処理等を行ってもよい。
実施例に示す通り、クランベリー抽出物は、皮膚の保湿、皮脂量調節、皮膚の弾力性保持、抹消血液循環保持等の機能を有するので、経口用皮膚改善剤として有用である。In addition, in order to concentrate and refine | purify the active ingredient in a cranberry extract, you may perform further solvent extraction, a synthetic adsorbent, an ion exchange resin process, etc.
As shown in the examples, the cranberry extract has functions such as moisturizing the skin, adjusting the amount of sebum, maintaining the elasticity of the skin, and maintaining the peripheral blood circulation, and thus is useful as an oral skin improvement agent.
皮膚の保湿とは、肌水分量を良好に保ち、肌のすべすべ感・なめらかさ・しっとりさなどを改善することである。 Moisturizing the skin means maintaining a good skin moisture content and improving the smoothness, smoothness and moistness of the skin.
皮脂量調節とは、皮脂量を良好に調節し、肌のあぶらっぽさ・ニキビ・吹き出物などを改善することである。 The adjustment of sebum amount means that the amount of sebum is adjusted well to improve the oiliness, acne, pimples, etc. of the skin.
皮膚の弾力性保持とは、肌弾力を良好に保ち、肌のはり・目の下のたるみなどを改善することである。 Keeping skin elasticity means maintaining good skin elasticity and improving skin tension and sagging under the eyes.
抹消血液循環保持とは、抹消血液循環機能を良好に保ち、冷え性などを改善することである。 The term “peripheral blood circulation maintenance” refers to maintaining good peripheral blood circulation function and improving cooling performance.
本発明の剤は、そのまま或いは飲食品、水または医薬品に添加して、液状または固形状で使用できる。経口用として使用可能であれば、剤としての形状は特に限定されず、錠剤、カプセル剤、顆粒剤、散剤、液剤とすることができる。有効成分の摂取量は、有効成分の濃縮・精製度合い、投与目的、使用者の皮膚の状態により適宜設定すればよく、例えば、経口用として使用する場合には、施用者の体重に対し、1日あたり、有効成分量として0.0001〜50g/kg、好ましくは0.0005〜25g/kg、更に好ましくは0.001〜10g/kg程度の量で用いられる。 The agent of the present invention can be used in liquid or solid form as it is or added to food and drink, water or pharmaceuticals. As long as it can be used for oral use, the form of the agent is not particularly limited, and it can be a tablet, capsule, granule, powder, or liquid. The intake of the active ingredient may be appropriately set according to the concentration / purification degree of the active ingredient, the purpose of administration, and the condition of the user's skin. For example, when used for oral use, The amount of active ingredient per day is 0.0001 to 50 g / kg, preferably 0.0005 to 25 g / kg, more preferably about 0.001 to 10 g / kg.
本発明の経口用皮膚改善剤は、継続して使用することが好ましく、少なくとも2週間、好ましくは、4週間以上、更に好ましくは8週間以上の継続使用が好ましい。 The oral skin improver of the present invention is preferably used continuously, and is preferably used continuously for at least 2 weeks, preferably 4 weeks or more, more preferably 8 weeks or more.
以下、実施例により、本発明のクランベリー抽出物の皮膚改善作用を確認する方法とその結果を示す。なお、本発明は、これらの実施例に限定されるものではない。 Hereinafter, methods for confirming the skin-improving action of the cranberry extract of the present invention and the results thereof are shown by Examples. The present invention is not limited to these examples.
(クランベリー抽出物の経口摂取による皮膚改善効果)
試験参加に同意を得た33〜38歳の健常人女性24名を対象に、試験群と対照群の2グループ(12名ずつ)に分けた。試験群には、市販の65%クランベリー果汁入り飲料(クランベリーUR65、キッコーマン株式会社)125mlを毎日朝夕1本ずつ飲用させた。対照群では、特に飲料の摂取を指定せずに、季節変動計測モニターとした。試験期間は4週間で、スタート時と4週間後に、自己申告による肌状態及び体調の変化、美容専門家による肌診断、肌水分量及び肌弾力、抹消血液循環機能の測定を行った。洗顔後23℃、湿度50%RHに調整した環境試験室内で20分間座位安静の後、各測定を実施した。(Skin improvement effect by oral intake of cranberry extract)
Twenty-four healthy women aged 33 to 38 who agreed to participate in the study were divided into two groups (12 subjects), a test group and a control group. In the test group, 125 ml of a commercially available beverage containing 65% cranberry juice (cranberry UR65, Kikkoman Corporation) was drunk daily in the morning and evening. In the control group, a seasonal variation measurement monitor was used without specifying drink intake. The test period was 4 weeks. At the start and after 4 weeks, changes in skin condition and physical condition by self-report, skin diagnosis by a beauty specialist, skin moisture content and elasticity, and measurement of peripheral blood circulation function were performed. Each measurement was carried out after sitting for 20 minutes in an environmental test chamber adjusted to 23 ° C. and humidity 50% RH after washing the face.
自己申告による肌状態および体調の変化は、アンケート調査によって行い、その変化を数値化した。スタート時を基準とした4週間後の自己評価による肌状態の変化を図1に示した。それぞれ12名の平均値では、試験群が対照群に比べて、すべての評価項目で改善傾向が見られた。特に、「あぶらっぽさ」、「はり」、「ニキビ・吹き出物」、「透明感」、「肌の総合評価」の項目は統計的に有意な差が認められた。この結果、試験群において、経口摂取による皮膚改善効果が確認された。 Changes in skin condition and physical condition due to self-report were conducted by questionnaire survey, and the changes were quantified. FIG. 1 shows changes in the skin condition by self-assessment after 4 weeks with reference to the start time. In the average value of 12 people, the test group showed an improvement trend in all the evaluation items compared with the control group. In particular, statistically significant differences were observed in the items of “oiliness”, “beam”, “acne / pimple”, “transparency”, and “overall skin evaluation”. As a result, the skin improvement effect by oral ingestion was confirmed in the test group.
美容専門家による肌診断は、視診・触診にて行い、その変化を数値化した。スタート時を基準とした4週間後の視診・触診による肌状態の変化を図2に示した。それぞれ12名の平均値では、試験群が対照群に比べて、すべての評価項目で改善傾向が見られた。特に、「目尻のしわ」、「目の下のたるみ」、「はりのよさ」、「肌の総合評価」の項目は統計的に有意な差が認められた。この結果、試験群において、経口摂取による皮膚改善効果が確認された。 Skin diagnosis by a beauty specialist was performed by visual inspection and palpation, and the changes were quantified. FIG. 2 shows changes in skin condition due to visual inspection and palpation after 4 weeks with reference to the start time. In the average value of 12 people, the test group showed an improvement trend in all the evaluation items compared with the control group. In particular, statistically significant differences were observed in the items of “eye wrinkles”, “sagging under eyes”, “goodness of elasticity”, and “overall skin evaluation”. As a result, the skin improvement effect by oral ingestion was confirmed in the test group.
肌水分量は、電気伝導度型商品名SKICON−200(IBS社製)を用いて、頬中央部位の角層水分量を測定した。その結果、スタート時を基準とした4週間後の水分量の変化量は、試験群で+6.9μS、対照群で−0.7μSとなり、試験群で良好な皮膚保湿効果が認められた。自己申告による「すべすべ」の改善、触診による「なめらかさ」、「しっとりさ」の改善の結果と考え合わせて、本発明の経口用皮膚改善剤が、皮膚の保湿の機能を有していることがわかる。 The skin moisture content was determined by measuring the moisture content of the stratum corneum at the cheek center using an electrical conductivity type trade name SKICON-200 (manufactured by IBS). As a result, the amount of change in the amount of water after 4 weeks with respect to the start time was +6.9 μS in the test group and −0.7 μS in the control group, and a good skin moisturizing effect was observed in the test group. The oral skin improvement agent of the present invention has a function of moisturizing the skin in combination with the results of improvement of “smoothness” by self-reporting, “smoothness” and “moistness” by palpation. I understand.
皮脂量は、透過光比率型セブメーターを用いて左側の眉上の皮脂レベルを測定し、パターン化して判定した。その結果、スタート時を基準とした4週間後の皮脂量判定は、試験群で改善4名、変化なし4名、悪化4名、対照群で改善0名、変化なし7名、悪化5名となった。このことは、試験期間中に季節変動計測モニターである対照群で悪化した皮脂量が、試験群では維持されていることを示す。自己申告による「あぶらっぽさ」、「ニキビ・吹き出物」の改善の結果と考え合わせて、本発明の経口用皮膚改善剤が、皮脂量調節の機能を有していることがわかる。 The amount of sebum was determined by measuring the sebum level on the left eyebrow using a transmitted light ratio type cebumeter and patterning it. As a result, the amount of sebum after 4 weeks on the basis of the starting time was 4 improvement in the test group, 4 unchanged, 4 worse, 0 improved in the control group, 7 no change, 5 worse became. This indicates that the amount of sebum that deteriorated in the control group, which is a seasonal variation monitor during the test period, is maintained in the test group. Considering the results of the improvement of “oiliness” and “acne / pimple” by self-reporting, it can be seen that the oral skin improvement agent of the present invention has a function of regulating sebum amount.
肌弾力は、キュートメーターSEM575(インテグラル社製)を用い、右側の頬骨上部位の肌弾力(吸引戻り率)を測定した。その結果、スタート時を基準とした4週間後の肌弾力の変化率は、試験群で+5.9%、対照群で−3.9%となり、試験群で良好な皮膚弾力性の改善効果が認められた。自己申告による「はり」の改善、視診による「目の下のたるみ」の改善、触診による「はりのよさ」の改善の結果と考え合わせて、本発明の経口用皮膚改善剤が、皮膚の弾力性保持の機能を有していることがわかる。 The skin elasticity was measured by using a cute meter SEM575 (manufactured by Integral Co., Ltd.) and measuring the skin elasticity (suction return rate) of the region on the right cheekbone. As a result, the rate of change in skin elasticity after 4 weeks with reference to the start time was + 5.9% in the test group and -3.9% in the control group, which showed a good skin elasticity improvement effect in the test group. Admitted. Combined with the results of self-reported improvement of “beam”, improvement of “sag under the eyes” by visual inspection, and improvement of “goodness of beam” by palpation, the oral skin improvement agent of the present invention maintains the elasticity of the skin. It turns out that it has the function of.
抹消血液循環機能は、BCチェッカー(加速度脈波測定システム、フューチャー・ウエイブ社製)を使って、人差し指尖をセンサー部分にのせ、指尖脈波をスコアー値として測定した。その結果、スタート時を基準とした4週間後の抹消血液循環機能スコアー値の変化量は、試験群で+3.9、対照群で−23.9となった。このことは、試験期間中に季節変動計測モニターである対照群で悪化した抹消血液循環機能が、試験群では維持されていることを示す。自己申告による「冷え性」の改善の結果と考え合わせて、本発明の経口用皮膚改善剤が、抹消血液循環保持の機能を有していることがわかる。 The peripheral blood circulation function was measured using a BC checker (acceleration pulse wave measurement system, manufactured by Future Wave) with the index fingertip placed on the sensor portion and the fingertip pulse wave as a score value. As a result, the amount of change in the peripheral blood circulation function score value after 4 weeks with respect to the start time was +3.9 in the test group and -23.9 in the control group. This indicates that the peripheral blood circulation function deteriorated in the control group, which is a seasonal variation monitor during the test period, is maintained in the test group. Considering the result of improvement of “coolability” by self-reporting, it can be seen that the oral skin improvement agent of the present invention has a function of maintaining peripheral blood circulation.
本発明の経口用皮膚改善剤は、皮膚の保湿、皮脂量調節、皮膚の弾力性保持、抹消血液循環保持等の機能を有しており、医薬品、食品の分野において有用である。 The oral skin improvement agent of the present invention has functions such as skin moisturization, sebum amount adjustment, skin elasticity retention, peripheral blood circulation retention, and the like, and is useful in the fields of pharmaceuticals and foods.
Claims (8)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004042208 | 2004-02-19 | ||
JP2004042208 | 2004-02-19 | ||
PCT/JP2005/002554 WO2005079825A1 (en) | 2004-02-19 | 2005-02-18 | Oral skin remedy containing cranberry extract as active ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2005079825A1 JPWO2005079825A1 (en) | 2007-10-25 |
JP4666652B2 true JP4666652B2 (en) | 2011-04-06 |
Family
ID=34879248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006510238A Expired - Fee Related JP4666652B2 (en) | 2004-02-19 | 2005-02-18 | Oral skin improver containing cranberry extract as an active ingredient |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP4666652B2 (en) |
TW (1) | TW200528033A (en) |
WO (1) | WO2005079825A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102541810B1 (en) * | 2023-01-05 | 2023-06-13 | 한국콜마주식회사 | Compositions for improving skin comprising angelica and cranberry extracts and uses thereof |
KR102556457B1 (en) * | 2023-04-12 | 2023-07-18 | 주식회사 상상바이오 | A whitening composition derived from natural products containing a large amount of lipoic acid |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008239620A (en) * | 2007-03-01 | 2008-10-09 | Kazuko Hirai | Antiallergic agent containing cranberry fruit juice as active ingredient |
FR2930153B1 (en) * | 2008-04-21 | 2012-05-04 | Oreal | USE OF A BAY EXTRACT, AND ESPECIALLY WOLFBERRY, FOR THE TREATMENT OF DROUGHT KERATINIC MATTER |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001261547A (en) * | 2000-03-22 | 2001-09-26 | Kanebo Ltd | Cosmetic |
JP2002003361A (en) * | 2000-06-26 | 2002-01-09 | Kanebo Ltd | Bleaching agent and cosmetic |
JP2002012531A (en) * | 2000-06-27 | 2002-01-15 | Kao Corp | Hair dye composition |
JP2002293736A (en) * | 2001-03-30 | 2002-10-09 | Sunstar Inc | Maillard reaction inhibitor and composition containing the same |
JP2002538802A (en) * | 1999-03-12 | 2002-11-19 | ラボラトワール アルコファルマ | Food supplement and method for cosmetic treatment based on grape extract rich in polyphenols |
JP2002363088A (en) * | 2001-06-08 | 2002-12-18 | Ichimaru Pharcos Co Ltd | Elastase activity inhibitor or cosmetic composition |
JP2003040758A (en) * | 2001-07-25 | 2003-02-13 | Matsukawa Kagaku:Kk | Cosmetic |
JP2004123707A (en) * | 2002-07-29 | 2004-04-22 | Toyo Shinyaku:Kk | Blood circulation-ameliorating composition |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001342142A (en) * | 2000-06-01 | 2001-12-11 | Nissui Pharm Co Ltd | Composition for preventing and curing urologic disease |
JP3568201B1 (en) * | 2002-07-29 | 2004-09-22 | 株式会社東洋新薬 | Health foods and beverages |
-
2005
- 2005-02-18 WO PCT/JP2005/002554 patent/WO2005079825A1/en active Application Filing
- 2005-02-18 TW TW094104799A patent/TW200528033A/en unknown
- 2005-02-18 JP JP2006510238A patent/JP4666652B2/en not_active Expired - Fee Related
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002538802A (en) * | 1999-03-12 | 2002-11-19 | ラボラトワール アルコファルマ | Food supplement and method for cosmetic treatment based on grape extract rich in polyphenols |
JP2001261547A (en) * | 2000-03-22 | 2001-09-26 | Kanebo Ltd | Cosmetic |
JP2002003361A (en) * | 2000-06-26 | 2002-01-09 | Kanebo Ltd | Bleaching agent and cosmetic |
JP2002012531A (en) * | 2000-06-27 | 2002-01-15 | Kao Corp | Hair dye composition |
JP2002293736A (en) * | 2001-03-30 | 2002-10-09 | Sunstar Inc | Maillard reaction inhibitor and composition containing the same |
JP2002363088A (en) * | 2001-06-08 | 2002-12-18 | Ichimaru Pharcos Co Ltd | Elastase activity inhibitor or cosmetic composition |
JP2003040758A (en) * | 2001-07-25 | 2003-02-13 | Matsukawa Kagaku:Kk | Cosmetic |
JP2004123707A (en) * | 2002-07-29 | 2004-04-22 | Toyo Shinyaku:Kk | Blood circulation-ameliorating composition |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102541810B1 (en) * | 2023-01-05 | 2023-06-13 | 한국콜마주식회사 | Compositions for improving skin comprising angelica and cranberry extracts and uses thereof |
KR102556457B1 (en) * | 2023-04-12 | 2023-07-18 | 주식회사 상상바이오 | A whitening composition derived from natural products containing a large amount of lipoic acid |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005079825A1 (en) | 2007-10-25 |
WO2005079825A1 (en) | 2005-09-01 |
TW200528033A (en) | 2005-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5654731B2 (en) | Cyanobacteria extract powder, method for producing the same, and use of Cyanobacteria extract powder | |
KR102239121B1 (en) | Sugar-free pineapple extract, method for producing the extract, and application of the extract | |
CN111053716B (en) | Application of Fuzhuan tea extract in preparation of skin conditioning product | |
JP2009126863A (en) | Composition highly containing ergothioneine extracted from mushroom | |
JP2002293736A (en) | Maillard reaction inhibitor and composition containing the same | |
JP4666652B2 (en) | Oral skin improver containing cranberry extract as an active ingredient | |
JP6096943B2 (en) | Food and beverage composition | |
JP4593474B2 (en) | Tyrosinase activity inhibitor and facial blood flow improving agent | |
KR102472974B1 (en) | Composition for improving skin | |
KR102209663B1 (en) | Composition for preventing or treating skin disease comprising extract of Spiraea prunifolia simpliciflora | |
JP2021109869A (en) | AGE production inhibitor | |
KR20230120619A (en) | Composition for improving skin conditions | |
JP2003171300A (en) | Melanization inhibitor | |
JP4247091B2 (en) | Skin anti-aging agent | |
KR20150143738A (en) | 1,5-anhydro-d-glucitol-containing collagen production accelerator | |
JP7007788B2 (en) | Pore conspicuous prevention / improvement agent | |
JP2005281271A (en) | Skin moisturizing ability improving agent | |
KR20210002047A (en) | Composition for antiaging comprising hydrolysates from Scomberomorus niphonius | |
JP4902967B2 (en) | Melanin production inhibitor | |
JPH09118627A (en) | Medicine containing 'tencha' extract as active ingredient and food product and cosmetic containing the same | |
KR101661423B1 (en) | anti-oxidant and anti-inflammation composition extracted from Isodon excisus, and its extracting method | |
KR20190036975A (en) | Compositions for Improving Skin Wrinkles and Skin Whitening Using an Extract of Polygonum japonica | |
KR20170025364A (en) | Composition for improving skin | |
KR20160082317A (en) | A composition for skin comprising extract of Lonicera caerulea fruits | |
TW202116290A (en) | Use of sea berry (hippophaerhamnoides) extract for improving skin condition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100831 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101029 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101124 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101201 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110105 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110107 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140121 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |